Pfizer, GSK, and Moderna Struggle in the Shrinking RSV Vaccine Market
Thursday, 7 November 2024, 19:53
Market Overview: RSV Vaccine Challenges
The U.S. vaccine landscape for respiratory syncytial virus (RSV) is witnessing a notable contraction, significantly impacting key players like Pfizer, GSK, and Moderna. Moderna's recent Q3 results underscore this trend, revealing diminishing revenues tied to RSV vaccines.
Key Factors Influencing the Market
- Market Demand: A declining demand for RSV vaccines has been noted, as indicated in recent sales reports.
- Competitive Landscape: Increased competition among major companies has put pressure on pricing and market share.
- Regulatory Environment: Changes in regulations and approval processes are impacting market entry strategies.
As Pfizer continues to navigate these challenges, understanding the underlying market dynamics becomes crucial for stakeholders.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.